Form 4: Acrivon Therapeutics CFO Rasmus Holm-Jorgensen Acquires Stock Options

Acrivon Therapeutics' Chief Financial Officer, Rasmus Holm-Jorgensen, was granted stock options for 90,090 shares on March 1, 2024.

Summary

• Rasmus Holm-Jorgensen, the Chief Financial Officer of Acrivon Therapeutics, Inc., was granted stock options to purchase 90,090 shares of common stock.
• The options were granted on March 1, 2024, with an exercise price of $5.70 per share.
• The options vest over time, with 25% vesting on March 1, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The vesting is contingent upon Mr. Holm-Jorgensen's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The vesting schedule of the stock options is designed to incentivize the CFO's continued service and contribution to the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• Vesting schedules, like the one described, are typical to ensure long-term commitment from executives.
• The specific terms of the grant, such as the exercise price and vesting schedule, are likely comparable to those offered by similar companies in the sector.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CFO's interests with the company's long-term performance.
• The vesting schedule encourages the CFO's continued service, which is beneficial for the company's stability.

Key Dates

Keywords

stock options, insider trading, executive compensation, Acrivon Therapeutics, ACRV, Rasmus Holm-Jorgensen, CFO